Reveal Biosciences is a computational pathology company founded in 2012 in the United States. The company leverages traditional histopathology and artificial intelligence to convert tissue biology into actionable data. Their technology pipeline encompasses a high-plex multiplex platform and machine learning computational pathology solutions, which empower research, diagnostics, and clinical labs to analyze tissue samples more accurately and efficiently.
Reveal Biosciences serves various industries including AI, Biopharma, Biotechnology, and Health Care. Their advanced tissue technologies, such as immunohistochemistry (IHC), in situ hybridization (ISH), histology, digital pathology, and image analysis services, cater to a diverse clientele comprising pharmaceutical, biotech, academic, and government institutions.
The company received a Series A investment on 02 April 2019 from prominent investors including Intel Capital, PP Capital, and GNI Japan, demonstrating confidence in Reveal Biosciences' potential to innovate in the intersection of pathology and AI.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 3 |
|
02 Apr 2019 |
No recent news or press coverage available for Reveal Biosciences.
We care about your data, and we'd love to use cookies make your experience better.
